Evidence map›Paper›PMID 34015541›Full record

ArticleDrug discovery today2021

Converging global crises are forcing the rapid adoption of disruptive changes in drug discovery.

J Mark Treherne, Gillian R Langley

Open access · greenAbstract read
In one paragraph

Article in Drug discovery today, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

J Mark TreherneTalisman Therapeutics Limited, Babraham Research Campus, Cambridge CB22 3AT, UK. Electronic address: mark@talisman-therapeutics.com.
Gillian R LangleyIndependent Consultant, Hitchin, UK.
Hitchin Hospital · GBTalisman Energy · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spiralling research costs combined with urgent pressures from the Coronavirus 2019 (COVID-19) pandemic and the consequences of climate disruption are forcing changes in drug discovery. Increasing the predictive power of in vitro human assays and using them earlier in discovery would refocus resources on more successful research strategies and reduce animal studies. Increasing laboratory automation enables effective social distancing for researchers, while allowing integrated data capture from remote laboratory networks. Such disruptive changes would not only enable more cost-effective drug discovery, but could also reduce the overall carbon footprint of discovering new drugs.

Indexed as

Artificial IntelligenceClimate ChangeCOVID-19Disruptive TechnologyDrug DiscoveryAutomationCarbon FootprintCooperative BehaviorData AccuracyHumansIn Vitro TechniquesMachine LearningPhysical DistancingSARS-CoV-2Advanced human cell and tissue modelsAOPsArtificial intelligenceClimate disruptionCOVID-19Decision theoryDrug pipeline attritionLaboratory automationMachine learning

Identifiers

PMID34015541
PMCPMC8129828
OpenAlexW3161386359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.